



ASX Announcement and Media Release

(ASX:SIE)

RESULTS OF ANNUAL GENERAL MEETING

Wednesday 29 June 2011

SciGen Ltd wishes to advise that all resolutions contained in the Notice of Annual General Meeting were duly voted on in accordance with Section 251 AA of the Corporations Act 2001 and ASX Listing Rule 3.13.2

The following information is provided in relation to the resolutions considered by shareholders at the Annual General Meeting held on 29 June 2011 at 9.30am in Singapore.

RESOLUTION	DESCRIPTION	FOR	AGAINST	ABSTAIN	NO INSTRUCTION	RESULT
1	Adoption of the Audited Accounts - 31 December 2010	500,333,785	-	-	-	CARRIED
2	Re-election of Mr Kenneth Gross	500,254,505	79,280	-	-	CARRIED
3	Re-election of Mr Adam Wilczega	500,254,505	79,280	-	-	CARRIED
4	Re-election of Mr Adam Polonek	500,254,505	79,280	-	-	CARRIED
5	Re-election of Mr Adam Aleksandrowicz	500,213,361	120,424	-	-	CARRIED
6	Re-Appointment of Auditors	500,292,794	40,991	-	-	CARRIED
7	Directors Remuneration - 31 December 2010	500,089,131	122,499	-	-	CARRIED
8	Authority to Allot & Issue Shares	500,210,439	123,346	-	-	CARRIED

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes a third generation Hepatitis B Vaccine and therapeutics such as rhuman Growth Hormone, rhuman Insulin and GCSF.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, Vietnam, China, India, Israel and Philippines, distribution channels in China, Hong Kong, India, Indonesia, Malaysia, Pakistan and Thailand, manufacturing facilities in Israel, India and China and a contract manufacturer in Poland, Bioton S.A.

For further information: Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: gdunlop@scigen.com.au	Slawomir Ziegert CEO SciGen Ltd +65 6779 6638